ASCO 2020 Kidney Cancer

Viewing 1-19 of 19 articles

ASCO 2020: PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704)

ASCO 2020: Discussant: Rare Variant Histologies in Renal Cell Carcinoma: Making the Unclear Be More Clear

ASCO 2020: Association of Gene Expression with Clinical Outcomes in Patients with Renal Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-427

ASCO 2020: Evaluation of Predictive Biomarkers for Nivolumab in Patients with Metastatic Clear Cell Renal Cell Carcinoma from the CheckMate-025 Trial

ASCO 2020: Phase II trial of Lenvatinib plus Pembrolizumab for Disease Progression after PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma

ASCO 2020: A Phase Ib Trial of Neoadjuvant/Adjuvant Durvalumab +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

ASCO 2020: COSMIC-313 Phase III Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Patients with Previously Untreated Advanced Renal Cell Carcinoma of Intermediate or Poor-Risk

ASCO 2020: Single Agent PD-1 Inhibitor Biomarkers in Untreated and Previously Treated Advanced RCC: What Can Biomarkers Teach Us to Advance Clinical Care?

ASCO 2020: A Phase III, Randomized, Placebo-Controlled Trial of Nivolumab or Nivolumab plus Ipilimumab in Patients with Localized Renal Cell Carcinoma at High-Risk of Relapse after Radical or Partial Nephrectomy (CheckMate 914)

ASCO 2020: Immunogenomic Characterization of Advanced Clear Cell Renal Cell Carcinoma Treated with PD-1 Blockade

ASCO 2020: Emerging Unmet Needs in RCC: An Ideal Sequential Strategy and the Post-Immunotherapy Space

ASCO 2020: Results from a Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer or Sporadic Papillary Renal Cell Cancer

ASCO 2020: KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma

ASCO 2020: Phase II Study of the Oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau Disease–Associated Renal Cell Carcinoma

ASCO 2020: FRACTION-RCC: Innovative, High-Throughput Assessment of Nivolumab + Ipilimumab for Treatment-Refractory Advanced Renal Cell Carcinoma

ASCO 2020: OMNIVORE: Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma

ASCO 2020: SAVOIR: A Phase III Study of Savolitinib versus Sunitinib in Patients with MET-Driven Papillary Renal Cell Carcinoma

ASCO 2020: Biomarker Analyses from the Phase III CheckMate 214 Trial of Nivolumab plus Ipilimumab or Sunitinib in Advanced Renal Cell Carcinoma

ASCO 2020: Biomarkers of Single-Agent versus Combination Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

email news signup